These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24396655)

  • 1. Olanzapine-induced diabetic ketoacidosis and neuroleptic malignant syndrome with rhabdomyolysis: a case report.
    Sa YK; Yang H; Jung HK; Son JW; Lee SS; Kim SR; Cha BY; Son HY; Pae CU; Yoo SJ
    Endocrinol Metab (Seoul); 2013 Mar; 28(1):70-5. PubMed ID: 24396655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S; Kornreich C; Choubani Z; Gourevitch R
    Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine-Induced Neuroleptic Malignant Syndrome.
    Hosseini S; Elyasi F
    Iran J Med Sci; 2017 May; 42(3):306-309. PubMed ID: 28533580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
    Croarkin PE; Emslie GJ; Mayes TL
    J Clin Psychiatry; 2008 Jul; 69(7):1157-65. PubMed ID: 18572981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.
    Polcwiartek C; Vang T; Bruhn CH; Hashemi N; Rosenzweig M; Nielsen J
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3663-3672. PubMed ID: 27592232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.
    Vuk A; Kuzman MR; Baretic M; Osvatic MM
    Psychiatr Danub; 2017 Jun; 29(2):121-135. PubMed ID: 28636569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine.
    Ramaswamy K; Kozma CM; Nasrallah H
    Drug Saf; 2007; 30(7):589-99. PubMed ID: 17604410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic malignant syndrome in a patient on long-term olanzapine treatment at a stable dose: Successful treatment with dantrolene.
    Kouparanis A; Bozikas A; Spilioti M; Tziomalos K
    Brain Inj; 2015; 29(5):658-60. PubMed ID: 25625410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam.
    Yacoub A; Francis A
    Neuropsychiatr Dis Treat; 2006 Jun; 2(2):235-40. PubMed ID: 19412469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic.
    Abu-Kishk I; Toledano M; Reis A; Daniel D; Berkovitch M
    J Toxicol Clin Toxicol; 2004; 42(6):921-5. PubMed ID: 15533033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical neuroleptic malignant syndrome - A case report.
    Vellekkatt F; Kuppili PP; Bharadwaj B; Menon V
    Asian J Psychiatr; 2019 Jun; 43():7-8. PubMed ID: 31071486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine-associated neuroleptic malignant syndrome.
    Norgard NB; Stark JE
    Pharmacotherapy; 2006 Aug; 26(8):1180-2. PubMed ID: 16863495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine-induced Neuroleptic Malignant Syndrome.
    Saha PK; Chakraborty A; Layek AK; Chakraborty A
    Indian J Psychol Med; 2017; 39(3):364-365. PubMed ID: 28615778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sudden discontinuation and reinstitution of olanzapine-associated atypical neuroleptic malignant syndrome in a patient undergoing lung surgery.
    Zhao Z; Zhang H; Wang S; Chen X
    Int J Clin Exp Med; 2015; 8(7):11639-41. PubMed ID: 26379999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.
    Järventausta K; Leinonen E
    Acta Psychiatr Scand; 2000 Sep; 102(3):231-3. PubMed ID: 11008860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.
    Stevens DL; Lee MR; Padua Y
    Pharmacotherapy; 2008 Mar; 28(3):403-5. PubMed ID: 18294120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical neuroleptic malignant syndrome associated with olanzapine.
    Reeves RR; Torres RA; Liberto V; Hart RH
    Pharmacotherapy; 2002 May; 22(5):641-4. PubMed ID: 12013364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome.
    Musselman ME; Browning LA; Parker D; Saely S
    Ann Pharmacother; 2011 Nov; 45(11):e61. PubMed ID: 21972252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.